FDA grants new Genmab drug priority review status

The US health authority FDA has accepted Genmab and Seagen's application for a biologics license application relating to their product tisotumab vedotin.

Genmab CEO Jan van de Winkel | Photo: PR / Genmab

On Friday evening, partners Genmab and Seagen announced that the US Food and Drug Administration (FDA) has accepted their biologics license application (BLA) in the US for tisotumab vedotin for treating recurrent or metastatic cervical cancer with disease progression during or after chemotherapy.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs